Postpartum Depression
... Major depression with postpartum onset 5 of the following: n Depressed mood* n Decreased interest or pleasure* n Appetite disturbance n Sleep Disturbance n Physical agitation or psychomotor slowing n Fatigue, decreased energy n Feeling of worthlessness or excess guilt n Decreased con ...
... Major depression with postpartum onset 5 of the following: n Depressed mood* n Decreased interest or pleasure* n Appetite disturbance n Sleep Disturbance n Physical agitation or psychomotor slowing n Fatigue, decreased energy n Feeling of worthlessness or excess guilt n Decreased con ...
Evidence-based treatment for Depersonalisation
... panic disorder, posttraumatic stress disorder, schizophrenia, stress and fatigue, (Medford 2012)), or it may occur as a primary phenomenon, in which case it is classified as depersonalisation-derealisation disorder (Simeon et al. 1997). DPRD is frequently a chronic disorder, affecting between 1% and ...
... panic disorder, posttraumatic stress disorder, schizophrenia, stress and fatigue, (Medford 2012)), or it may occur as a primary phenomenon, in which case it is classified as depersonalisation-derealisation disorder (Simeon et al. 1997). DPRD is frequently a chronic disorder, affecting between 1% and ...
Evidence-based treatment for Depersonalisation-derealisation Disorder (DPRD) Open Access
... panic disorder, posttraumatic stress disorder, schizophrenia, stress and fatigue, (Medford 2012)), or it may occur as a primary phenomenon, in which case it is classified as depersonalisation-derealisation disorder (Simeon et al. 1997). DPRD is frequently a chronic disorder, affecting between 1% and ...
... panic disorder, posttraumatic stress disorder, schizophrenia, stress and fatigue, (Medford 2012)), or it may occur as a primary phenomenon, in which case it is classified as depersonalisation-derealisation disorder (Simeon et al. 1997). DPRD is frequently a chronic disorder, affecting between 1% and ...
Depression in Long-Term Care REVIEWS
... setting. The foundation of treatment is pharmacotherapy, yet other therapeutic approaches, such as exercise and psychological therapies may be of value. ...
... setting. The foundation of treatment is pharmacotherapy, yet other therapeutic approaches, such as exercise and psychological therapies may be of value. ...
Depression in childhood and adolescence: clinical features
... childhood and adolescence depression. Its objective is to provide clear information on this common, severe and not very easily recognized pathology. Sources: literature searches were performed through Medline (1991-2000), with secondary-source follow-up. Summary of the findings: scientific concern a ...
... childhood and adolescence depression. Its objective is to provide clear information on this common, severe and not very easily recognized pathology. Sources: literature searches were performed through Medline (1991-2000), with secondary-source follow-up. Summary of the findings: scientific concern a ...
Children and Adolescents` Depression and
... access to available means (SW, AFS) It is important to be explicit. Easy access to guns six to ten times increase for completed suicide. ( This gives a whole new meaning to live free or die). 5. Stress and protection in different family contexts. Level of discord in family or parent psychopathology. ...
... access to available means (SW, AFS) It is important to be explicit. Easy access to guns six to ten times increase for completed suicide. ( This gives a whole new meaning to live free or die). 5. Stress and protection in different family contexts. Level of discord in family or parent psychopathology. ...
6 slides/page - Wisconsin Alzheimer`s Institute
... Objectives—Agitation and aggression in Alzheimer’s disease (AD) is a major cause of patient distress, caregiver burden, and institutionalization. Enhanced behavioral responsiveness to central nervous system norepinephrine release may contribute to the pathophysiology of agitation and aggression in A ...
... Objectives—Agitation and aggression in Alzheimer’s disease (AD) is a major cause of patient distress, caregiver burden, and institutionalization. Enhanced behavioral responsiveness to central nervous system norepinephrine release may contribute to the pathophysiology of agitation and aggression in A ...
Melancholia and the probability and lethality of suicide attempts
... BURKE, PhD, J. JOHN MANN, MD, Department of Neuroscience, New York State Psychiatric Institute and Columbia University, New York, York, New York, USA Correspondence: Dr Michael F.Grunebaum, Department of Neuroscience, New York State Psychiatric Institute, 1051Riverside Drive, Box 42, New York, NY100 ...
... BURKE, PhD, J. JOHN MANN, MD, Department of Neuroscience, New York State Psychiatric Institute and Columbia University, New York, York, New York, USA Correspondence: Dr Michael F.Grunebaum, Department of Neuroscience, New York State Psychiatric Institute, 1051Riverside Drive, Box 42, New York, NY100 ...
Research Update - PTSD
... for Posttraumatic Stress Disorder Among Female Rape Survivors, J Consult Clin Psychol 2012 (Adapted with permission from Schnurr, APA 2012) ...
... for Posttraumatic Stress Disorder Among Female Rape Survivors, J Consult Clin Psychol 2012 (Adapted with permission from Schnurr, APA 2012) ...
Escitalopram and Problem-Solving Therapy for Prevention of
... Patients, family members, and primary care physicians were asked about adverse events such as physical illnesses or medication adverse effects at 3-month intervals or sooner if an individual reported an adverse event— using a standardized checklist developed for this study. A data and safety monitor ...
... Patients, family members, and primary care physicians were asked about adverse events such as physical illnesses or medication adverse effects at 3-month intervals or sooner if an individual reported an adverse event— using a standardized checklist developed for this study. A data and safety monitor ...
Self-esteem as a predictor of suicide risk among psychiatric patients
... Self-esteem has profound consequences for our existence (Branden, 1994). Baumeister, Campbell, Krueger, and Vohs (2003) explained that it is difficult, if not impossible, for people to remain indifferent to information that bears on their self-esteem, such as being told that they are incompetent, at ...
... Self-esteem has profound consequences for our existence (Branden, 1994). Baumeister, Campbell, Krueger, and Vohs (2003) explained that it is difficult, if not impossible, for people to remain indifferent to information that bears on their self-esteem, such as being told that they are incompetent, at ...
PDF - Research Review NZ
... the anticonvulsant lamotrigine on bipolar I depression and results indicated that the agent may have antidepressant efficacy.43 These findings kicked off the use of lamotrigine for bipolar I depression. A recent meta-analysis undertaken by Geddes and colleagues of data from 1072 patients from five r ...
... the anticonvulsant lamotrigine on bipolar I depression and results indicated that the agent may have antidepressant efficacy.43 These findings kicked off the use of lamotrigine for bipolar I depression. A recent meta-analysis undertaken by Geddes and colleagues of data from 1072 patients from five r ...
journal Current status of sublingual immunotherapy in the United States
... 300 index of reactivity (IR) 5-grass pollen sublingual tablet was performed in adults in the United States [9]. 473 subjects with documented grass pollen allergy by history and positive skin test and Rhinoconjunctivitis Total Symptom Score of 12 or greater (scale 0–18) during the prior grass pollen ...
... 300 index of reactivity (IR) 5-grass pollen sublingual tablet was performed in adults in the United States [9]. 473 subjects with documented grass pollen allergy by history and positive skin test and Rhinoconjunctivitis Total Symptom Score of 12 or greater (scale 0–18) during the prior grass pollen ...
Efficacy and Safety of Lisdexamfetamine for Treatment of Adults With
... Treatment with the antiobesity agent sibutramine hydrochloride demonstrated some efficacy in clinical trials; however, safety concerns led to market withdrawal.3,14-16 Antiepileptics also have been studied for BED, although they are associated with high rates of discontinuation.3,17,18 The most exte ...
... Treatment with the antiobesity agent sibutramine hydrochloride demonstrated some efficacy in clinical trials; however, safety concerns led to market withdrawal.3,14-16 Antiepileptics also have been studied for BED, although they are associated with high rates of discontinuation.3,17,18 The most exte ...
Adolescent subthreshold-depression and anxiety
... with dummy-coded SDQ impact score (0 ‘normal’ and 0 < ‘borderline/elevated scores’) and PSS total score (0 or greater) as independents, were conducted to explore the relationships between functional impairments, as well as suicidality and subthreshold and full anxiety/ depression. All analyses were ...
... with dummy-coded SDQ impact score (0 ‘normal’ and 0 < ‘borderline/elevated scores’) and PSS total score (0 or greater) as independents, were conducted to explore the relationships between functional impairments, as well as suicidality and subthreshold and full anxiety/ depression. All analyses were ...
... A Randomized Controlled Trial of Internet-Based Cognitive Therapy (iCT) and Standard Cognitive Therapy (CT) for Social Anxiety Disorder Investigating decision-making under single-dose Oxytocin in schizophrenia Prevention of major depression in at-risk adolescents: a pilot randomised controlled trial ...
Antipsychotics in children and adolescents
... More recently, the Treatment of Early Onset Schizophrenia Spectrum Disorders study (TEOSS), a larger, publicly funded, four-site, randomized, double-blind, controlled clinical trial, compared olanzapine (2.5–20 mg/day), risperidone (0.5–6.0 mg/day), and molindone (10–140 mg/day) for ...
... More recently, the Treatment of Early Onset Schizophrenia Spectrum Disorders study (TEOSS), a larger, publicly funded, four-site, randomized, double-blind, controlled clinical trial, compared olanzapine (2.5–20 mg/day), risperidone (0.5–6.0 mg/day), and molindone (10–140 mg/day) for ...
Suicidality, violence and mania caused by selective serotonin
... 4. Case studies related to SSRI-induced suicidality, violence, and extreme abnormal behavior in adults 4.1. Case reports of mania, violence, and suicide There are many case reports in the scientific literature documenting the capacity of SSRIs to cause mania in adults, often in association with irri ...
... 4. Case studies related to SSRI-induced suicidality, violence, and extreme abnormal behavior in adults 4.1. Case reports of mania, violence, and suicide There are many case reports in the scientific literature documenting the capacity of SSRIs to cause mania in adults, often in association with irri ...
Suicidality, violence and mania caused by selective serotonin
... 4. Case studies related to SSRI-induced suicidality, violence, and extreme abnormal behavior in adults 4.1. Case reports of mania, violence, and suicide There are many case reports in the scientific literature documenting the capacity of SSRIs to cause mania in adults, often in association with irri ...
... 4. Case studies related to SSRI-induced suicidality, violence, and extreme abnormal behavior in adults 4.1. Case reports of mania, violence, and suicide There are many case reports in the scientific literature documenting the capacity of SSRIs to cause mania in adults, often in association with irri ...
Document
... psychiatric disorders. Anyone considering the use of Pristiq or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. Short-term studies did not show an increase in the risk of suicidality with antidepressants compared to placebo in adults bey ...
... psychiatric disorders. Anyone considering the use of Pristiq or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. Short-term studies did not show an increase in the risk of suicidality with antidepressants compared to placebo in adults bey ...
Stassen et al.
... treatment and sometimes this even occurred later; (2) over 50% of the patients met criteria for ‘atypicality’, whereas only about 30% were ‘endogenous’, and (3) perhaps most importantly, improvement was measure by a global rating scale such that the patient had to be rated as either ‘very much impro ...
... treatment and sometimes this even occurred later; (2) over 50% of the patients met criteria for ‘atypicality’, whereas only about 30% were ‘endogenous’, and (3) perhaps most importantly, improvement was measure by a global rating scale such that the patient had to be rated as either ‘very much impro ...
Open poster - CTN Dissemination Library
... Overall, OROS-MPH was well-tolerated; had low abuse liability; good safety profile despite non-abstinence. There was no difference between OROS-MPH and placebo on primary ADHD and substance outcome measures, However, secondary outcome measures suggested some added benefit of OROS-MPH compared to pla ...
... Overall, OROS-MPH was well-tolerated; had low abuse liability; good safety profile despite non-abstinence. There was no difference between OROS-MPH and placebo on primary ADHD and substance outcome measures, However, secondary outcome measures suggested some added benefit of OROS-MPH compared to pla ...
September - EMDR International Association
... This regular column appears in each quarterly issue of the EMDRIA Newsletter and the EMDR Europe Newsletter. It lists citations, abstracts, and preprint/reprint information—when available—on all EMDR related journal articles. The listings include peer reviewed research reports and case studies direc ...
... This regular column appears in each quarterly issue of the EMDRIA Newsletter and the EMDR Europe Newsletter. It lists citations, abstracts, and preprint/reprint information—when available—on all EMDR related journal articles. The listings include peer reviewed research reports and case studies direc ...
Click here for handout
... risperidone and olanzapine versus haloperidol in teenagers with at least one positive psychotic symptoms. Methods: Subjects were between 8-19 years old and suffered p spectrum p disorders or affective disorders. In from schizophrenia all, 50 patients were studied over an 8 week period. Subjects were ...
... risperidone and olanzapine versus haloperidol in teenagers with at least one positive psychotic symptoms. Methods: Subjects were between 8-19 years old and suffered p spectrum p disorders or affective disorders. In from schizophrenia all, 50 patients were studied over an 8 week period. Subjects were ...
Study 329
Study 329 was a clinical trial conducted in North America from 1994 to 1998 to study the efficacy of paroxetine, an SSRI anti-depressant marketed as Paxil and Seroxat, in treating depressed teenagers. Paroxetine was released in 1991 by the British pharmaceutical company SmithKline Beecham, known since 2000 as GlaxoSmithKline (GSK). The drug made $11.6 billion between 1997 and 2006.Led by Martin Keller, then professor of psychiatry at Brown University, study 329 became controversial when it was discovered that the article in which the trial results were reported – published in 2001 in the Journal of the American Academy of Child and Adolescent Psychiatry (JAACAP) – had downplayed the trial's negative findings and had been ghostwritten by a PR firm hired by SmithKline Beecham. The controversy led to several lawsuits and strengthened calls for drug companies to disclose all their clinical research data. New Scientist wrote in 2015: ""You may never have heard of it, but Study 329 changed medicine.""The study, which compared paroxetine with imipramine, a tricyclic antidepressant marketed as Tofranil, failed to show efficacy for paroxetine in adolescent depression, something SmithKline Beecham acknowledged internally in 1998. In addition there were more examples of suicidal thinking and behaviour in the group taking paroxetine. Although the article included these negative results, it did not account for them in its conclusion. On the contrary, it concluded that paroxetine is ""generally well tolerated and effective for major depression in adolescents."" The company relied on the article to promote paroxetine for off-label use in teenagers.In 2003 Britain's Medicines and Healthcare Products Regulatory Agency (MHRA) analysed study 329 and other GSK studies of paroxetine. It concluded that there was no evidence of paroxetine's efficacy and a clear increase in suicidal behaviour in teenagers using it. The following month the MHRA and US Food and Drug Administration (FDA) advised doctors not to prescribe paroxetine to the under-18s. The MRHA launched a criminal inquiry into GSK's conduct, but announced in 2008 that there would be no charges. In 2004 New York State Attorney Eliot Spitzer sued GSK for having withheld the data. In 2012 the US Justice Department fined the company $3 billion, including a sum for withholding data on paroxetine, unlawfully promoting it for the under-18s, and preparing a misleading article about study 329.The JAACAP article on study 329 was never retracted. The journal's editors say the negative findings are included in a table, and that therefore there are no grounds to withdraw it. In September 2015 the BMJ published a re-analysis of study 329's data. This concluded that neither paroxetine nor imipramine had differed in efficacy in treating depression from placebo (an inert pill), that the paroxetine group had experienced more suicidal ideation and behaviour, and that the imipramine group had experienced more cardiovascular problems.